Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.48 |
| ▸ | TPH1 | P17752 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456664 | 0.86 | S1PR1 (0.56) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL451098 | 0.86 | S1PR1 (0.56) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL16591181 | 0.82 | S1PR1 (0.50) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL3456144 | 0.81 | S1PR1 (0.52) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL4741310 | 0.81 | S1PR1 (0.54) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL60775 | 0.81 | NPC1 (0.59) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL16591203 | 0.81 | S1PR1 (0.49) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL3455786 | 0.81 | S1PR1 (0.60) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL4741601 | 0.81 | S1PR1 (0.52) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL4741518 | 0.81 | S1PR1 (0.57) | S1PR1S1PR4S1PR5S1PR3TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258700-A1 | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | Pfizer Products Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258700-A1 | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | Pfizer Products Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-2021338-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Products Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | CCND1, CCND2, CCND3 | S1PR1 104/4885S1PR4 254/4885S1PR5 248/4885 |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCND1, CCND2, CCND3 | S1PR1 104/4885S1PR4 254/4885S1PR5 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.